A UK-led international clinical trial is recruiting 280 patients to see if the technique to remove cancerous cells could ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

A new tool can help physicians determine which patients with localized pancreatic neuroendocrine tumors (PanNETs) have an ...

For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...

Although active cancer is recognised as a risk factor for increased bleeding, the specific bleeding risks associated with ...

Individuals with CD who received treatment with biologics preoperatively have improved endoscopic outcomes when switching to a different biologic postoperatively.